Abstract: Interpretation of Potentially Curable Pancreatic Adenocarcinoma：ASCO Clinical Practice Guideline Update (Version 2019)        SUI Yu-hang，HU Ji-sheng，SUN Bei. Department of Pancreatic and Biliary Surgery,the First Affiliated Hospital of Harbin Medical University, Key Laboratory of Hepatosplenic Surgery, Ministry of Education, Haerbin 150001, China
Corresponding author：SUN Bei,E-mail：sunbei70@tom.com
Abstract    Pancreatic cancer is one of the most malignancy tumor in digestive system with extraordinarily poor prognosis owing to its difficulty in early diagnosis and complex treatments.Recently，great progress has been made in surgical techniques，adjuvant treatment and perioperative management of pancreatic cancer.However，the long-term survival of patients with pancreatic cancer has not been significantly improved. American Society of Clinical Oncology released clinical practice guidelines for potentially curable pancreatic cancer in 2016 and updated it for the first time in 2017.In 2019，American Society of Clinical Oncology renewed its guidelines in order to modify the program of postoperative adjuvant therapy for pancreatic cancer and recommend FOLFIRINOX as the first choice for postoperative adjuvant therapy for patients with pancreatic cancer in order to improve the prognosis of patients with pancreatic cancer.

Key words: potentially curable, pancreatic cancer, clinical practice guideline

摘要： 胰腺癌是消化系统中恶性程度最高的肿瘤之一，因早期诊断困难，治疗复杂导致其预后极差。近年来，胰腺癌的外科手术技术、辅助治疗及围手术期管理措施均取得了巨大进步，但胰腺癌病人的长期存活率并未得到显著改善。美国临床肿瘤协会于2016年针对潜在可治愈胰腺癌颁布了相应的临床实践指南，并于2017年首次更新。2019年，该组织围绕胰腺癌术后辅助治疗方案对潜在可治愈胰腺癌的临床实践指南再次更新，推荐FOLFIRINOX方案作为胰腺癌病人术后辅助治疗的首选方案，以期改善病人的预后。

关键词: 潜在可治愈, 胰腺癌, 临床实践指南